Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin cardiovascular and renal outcomes study in type 2 diabetes with moderate renal impairment
2017-002644-32Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sotagliflozin with Placebo (2 arms). Primary endpoint: Time to first Major Adverse Cardiovascular Event (MACE). Started Sep 2017; status: terminated.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-002644-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002644-32.